Digital Desk, Moscow. Post-registration trials of the Epivackorona vaccine against Kovid-19 have begun in Russia. According to media reports, Anna Popova, head of the Russian Federal Service for Consumer Protection and Welfare Affairs, gave this information on Tuesday. Russia became the first country to receive regulatory approval for a COVID-19 vaccine in August, when the Sputnik-V vaccine was officially registered with a large-scale clinical trial.
The Epivaccorona vaccine has now become the second Russian vaccine to receive regulatory approval, developed by the Vector State Research Center of Virology and Biotechnology. In an online program dedicated to Kovid-19 research, we can only prevent (Kovid-19) proliferation through vaccination, according to a Tas News Agency report. There are enough vaccines (vaccines) at high levels of development in the world. He said that Russia continues to develop the vaccine continuously.
The Vector Research Center received approval from the Russian Ministry of Health to conduct clinical trials of the vaccine on volunteers on 24 July. On July 27, the first volunteer received a vaccine shot. Popova previously reported that clinical trials for the vaccine had ended on September 30.
The report stated that the vaccine was registered on 14 October. Earlier, Russian Deputy Prime Minister Tatyana Golikova said that she had herself tested the Epivaccorona vaccine and did not experience any side effects. He had said, Vector Center is starting clinical trials after registration in various regions of Russia, which will include 40,000 volunteers.